UNSPSC 85601014: Supplement cecum via natural or artificial opening autologous tissue substitute, via natural or artificial opening

This classification denotes the group of activities that yields a surgical intervention or procedure to supplement cecum via natural or artificial opening autologous tissue substitute, via natural or artificial opening. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0DUH77Z

UNSPSC 85601014, Supplement cecum via natural or artificial opening autologous tissue substitute, via natural or artificial opening, is a Commodity code that shows little relevant recent activity under its nominal medical procedure scope. The six recent state and local contract opportunities posted under this code—ranging from independent medical evaluations for pension disability determinations and occupational health surveillance to pharmacy benefit management and temporary health professional staffing—bear no substantive connection to cecal supplementation or surgical tissue substitutes. The source records represent general healthcare administration, benefits management, and clinical staffing services rather than a specific surgical or implant product line. State and local governments do not appear to be actively soliciting cecal tissue substitutes or related surgical procedures through conventional procurement channels at present.

The mismatch between the code's clinical specificity and the actual opportunities posted suggests either systematic misclassification by issuing bodies or an absence of traditional procurement activity under this particular commodity designation. The recent opportunities span multiple jurisdictions—Arizona (City of Phoenix), California (City of Long Beach and County of Santa Clara), Washington (state ferries), Texas (Harris County), and Florida (Collier County)—but none involve the product category the code nominally describes. Procurement professionals evaluating this code should verify whether issuing bodies in their target markets are using alternative code assignments for any relevant tissue-substitute or surgical-procedure procurements, or whether acquisitions in this clinical area flow through different procurement vehicles such as hospital group purchasing organizations or integrated delivery system contracts that may not surface in standard state and local RFP databases.